ORKA

Oruka Therapeutics Inc

Add to Watchlist

Advanced Chart

27.750

-0.53(-1.874%)1D

Line

Candle

YTD

High

28.4301

Open

28.070

VWAP

27.52

Vol

517.23K

Mkt Cap

1.34B

Low

26.485

Amount

14.23M

EV/EBITDA(TTM)

Total Shares

48.38M

1.02B

EV/OCF(TTM)

P/S(TTM)

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

9 Analyst Rating

Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is 47.29 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 27.750

Low

40.00

Averages

47.29

High

60.00

Current: 27.750

Low

40.00

Averages

47.29

High

60.00

H.C. Wainwright

Mitchell Kapoor

Buy

downgrade

$45 -> $40

2025-10-27

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$45 -> $40

2025-10-27

downgrade

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor lowered the firm's price target on Oruka Therapeutics to $40 from $45 and keeps a Buy rating on the shares. The firm cites the company's recent equity financing for the target drop.

Guggenheim

NULL -> Buy

initiated

$60

2025-10-27

Reason

Guggenheim

Price Target

$60

2025-10-27

initiated

NULL -> Buy

Reason

Guggenheim initiated coverage of Oruka Therapeutics with a Buy rating and $60 price target, citing a positive view of its two highly optimized, best-in-class, longer-acting antibodies with validated targets. Although current biologics are highly efficacious with minimal safety risks, the firm believes Oruka's drugs could deliver rapid, deep and sustained responses with an ideal maintenance profile across multiple chronic immunology and inflammation indications, the analyst tells investors.

Clear Street

Kaveri Pohlman

Buy

initiated

$46

2025-08-20

Reason

Clear Street

Kaveri Pohlman

Price Target

$46

2025-08-20

initiated

Buy

Reason

Clear Street analyst Kaveri Pohlman initiated coverage of Oruka Therapeutics with a Buy rating and $46 price target. The firm views the stock's valuation as "compelling" following the 67% drop year-over-year. Oruka's "superior assets" are positioned to win market share in psoriasis, the analyst tells investors in a research note.

BTIG

NULL

Buy

initiated

$44

2025-05-22

Reason

BTIG

Price Target

$44

2025-05-22

initiated

NULL

Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$45

2025-02-07

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$45

2025-02-07

Reiterates

Strong Buy

Reason

Wolfe Research

Andy Chen

Buy

Initiates

$20

2025-02-04

Reason

Wolfe Research

Andy Chen

Price Target

$20

2025-02-04

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Oruka Therapeutics Inc (ORKA.O) is -11.80, compared to its 5-year average forward P/E of -6.14. For a more detailed relative valuation and DCF analysis to assess Oruka Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.14

Current PE

-11.80

Overvalued PE

-4.01

Undervalued PE

-8.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.66

Current PS

27.75

Overvalued PS

8.22

Undervalued PS

-4.90